Audited Supplier
In This Store
![1-(3-(Trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-4-(2,4,5-trifluorophenyl)](https://eimg.pharmasources.com/image/20240906/uajGW8wa47MPSDESYuAs2BuR9Ud8cPlp3ZcJU36x.png!280)
![2,7-Dichloro-alpha- [(dibutylamino)methyl]-9H fluorene-4-methanol (DBA)](https://eimg.pharmasources.com/image/20240906/Ofu0GtTgRcIHhQ3AXaMNyah3mVS3XuNdUJGWofv3.png!280)
![(1S,4R)-4-[(2-amino-6-chloro-5-formamido-4-pyrimidinyl)amino]-2-cyclopentene-1-methanol (AFC)](https://eimg.pharmasources.com/image/20240906/JUawwsPA3m2h3gAPjKAOTSdEJihP9F1frlpAS6bh.png!280)
Haorui, established in 1997, is a manufacturer and supplier of APIs, intermediates, veterinary and food additives. Meanwhile, it is assisting global pharmaceutical companies to get the domestic registration of their finished dosage for their international expansion. Our USFDA approved products Flumazenil, Granisetron HCl, Granisetron Base, Docetaxel Anhydrous, Irinotecan HCl, Dasatinib Monohydrate, Oxaliplatin and Temozolomide have been recognized by our customers globally. In addiction, our Amisulpride API accquired CEP, UK GMP & USDMF. Our USFDA approved factory, Hubei Haosun Pharma. Co., Ltd., is subject to cGMP. It is periodically inspected by China FDA, US FDA, EDQM, UK MHRA, Mexico Authority, etc. In 2018, we successfully passed the USFDA inspection with zero observation. Our fermented factory in Henan, is one of the leaders on development of natural food additives. It has been certified by GMP, ISO9001:2008 & ISO22000:2005, STAR-K Kosher(Judaic) and Halal Assurance(Islamic). Based on experience with NISIN&NATAMYCIN, we keep on creating innovative solutions to meet the demands of customers. Committed to quality, reliability and prosperity, Haorui will always be a partner you can count on.
Year of Establishment: 1997
Total Assets(USD):
Total Number of Staff:
Main Competitive Advantages:
Other Competitive Advantages:
Patents and Copyrights:
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us：
Pharma Sources Insight June 2024: Globalization on the Go
